makes aducanumab (Aduhelm) and lecanemab (Leqembi), which are the only two Alzheimer’s treatments licensed to treat the progression of the disease. While aducanumab’s approval by the US Food and Drug Administration in 2021 was controversial, given the ambiguous data over its efficacy and concerns about side effects, early indications are that
